Literature DB >> 2966808

Immediate effects of intravenous IgG administration on peripheral blood B and T cells and polymorphonuclear cells in patients with myasthenia gravis.

L Cook1, J F Howard, J D Folds.   

Abstract

Five patients with myasthenia gravis, who received treatment with intravenous 7S gamma-globulin were monitored for changes in immunological status. Serum immunoglobulin G increased from an average of 1.4 to 4.7 g/dl during the 5-day course of therapy. Specific antibody to the acetylcholine receptor present in three of five patients did not change. A transient decrease in total peripheral blood leukocytes was observed in five patients due to decreases in the absolute number of polymorphonuclear cells and lymphocytes in the circulation. Lymphocyte surface marker studies revealed that the percentage of surface immunoglobulin positive cells increased in all patients from an average of 13 to 26% by day 5 of therapy; however, the percentage of HLA-Dr- and Leu 12 (CD19)-positive B cells did not change. Lymphoid cells positive for the Leu 11 (CD16) marker doubled from an average of 11 to 24% during the 5-day course of therapy. Surface Ig-positive cells and Leu 11 (CD16)-positive cells returned to pretreatment values by 7 days posttherapy. Helper/suppressor cell ratios slowly decreased in all patients from an average of 2.9 to 2.2 by 1 week posttherapy and remained low for several weeks.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2966808     DOI: 10.1007/bf00915153

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  37 in total

1.  Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura.

Authors:  J F Delfraissy; G Tchernia; Y Laurian; C Wallon; P Galanaud; J Dormont
Journal:  Br J Haematol       Date:  1985-06       Impact factor: 6.998

2.  Transient deficiency of peripheral blood accessory cells in supporting T cell mitogenesis in patients suffering from chronic idiopathic thrombocytopenic purpura after intravenous gammaglobulin treatment.

Authors:  L M Larocca; N Maggiano; G Leone; M Piantelli; D Scribano; P Musiani
Journal:  Blut       Date:  1985-07

3.  Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

Authors:  Y Sultan; M D Kazatchkine; P Maisonneuve; U E Nydegger
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

4.  Interleukin-2 augments natural killer cell activity.

Authors:  C S Henney; K Kuribayashi; D E Kern; S Gillis
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

5.  Intravenous IgG for patients with spontaneous inhibitor to Factor VIII.

Authors:  R Zimmermann; B Kommerell; J Harenberg; W Eich; K Rother; K Schimpf
Journal:  Lancet       Date:  1985-02-02       Impact factor: 79.321

6.  High-dose intravenous gammaglobulin for myasthenia gravis.

Authors:  P Gajdos; H Outin; D Elkharrat; D Brunel; P de Rohan-Chabot; J C Raphael; M Goulon; C Goulon-Goeau; E Morel
Journal:  Lancet       Date:  1984-02-18       Impact factor: 79.321

7.  Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.

Authors:  J Fehr; V Hofmann; U Kappeler
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

8.  High-dose immunoglobulin in Felty's syndrome.

Authors:  M Ahern; J Harkness; P Maddison; S Forskitt
Journal:  Ann Rheum Dis       Date:  1983-08       Impact factor: 19.103

9.  IgG therapy in systemic lupus erythematosus--two case reports.

Authors:  G Gaedicke; W M Teller; E Kohne; R Dopfer; D Niethammer
Journal:  Blut       Date:  1984-06

10.  Comparison of antigenic sources for acetylcholine receptor antibody assays in myasthenia gravis.

Authors:  M W McAdams; A D Roses
Journal:  Ann Neurol       Date:  1980-07       Impact factor: 10.422

View more
  8 in total

1.  Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies.

Authors:  R Liblau; P Gajdos; F A Bustarret; R el Habib; J F Bach; E Morel
Journal:  J Clin Immunol       Date:  1991-05       Impact factor: 8.317

2.  Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin.

Authors:  N Kondo; T Ozawa; K Mushiake; F Motoyoshi; T Kameyama; K Kasahara; H Kaneko; M Yamashina; Y Kato; T Orii
Journal:  J Clin Immunol       Date:  1991-05       Impact factor: 8.317

Review 3.  Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders.

Authors:  S A Schwartz
Journal:  J Clin Immunol       Date:  1990-03       Impact factor: 8.317

4.  High-dose intravenous immunoglobulin in myasthenia gravis.

Authors:  A Evoli; M T Palmisani; E Bartoccioni; L Padua; P Tonali
Journal:  Ital J Neurol Sci       Date:  1993-04

5.  Intravenous immune globulin in the Guillain-Barré syndrome.

Authors:  F G van der Meché
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

Review 6.  In vitro effects of polyvalent immunoglobulin for intravenous use.

Authors:  I N van Schaik; M Vermeulen; A Brand
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 7.  Experience with intravenous immunoglobulin in myasthenia gravis: a review.

Authors:  G Edan; F Landgraf
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 8.  The use of IVIG in neurological disease.

Authors:  A I Levinson
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.